Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.

ABSTRACT:

Background

Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are frequently comorbid.

Aims

To assess the effectiveness of vortioxetine in patients with MDD and comorbid GAD.

Methods

Open-label, 8-week study (NCT04220996) in 100 adult outpatients with severe MDD and severe comorbid GAD receiving vortioxetine as first treatment for the current depressive episode or switching to vortioxetine due to inadequate response to another drug for depression. Vortioxetine starting dosage was 10 mg/day, with forced up-titration to 20 mg/day after 1 week. Response was defined as ⩾50% decrease in Montgomery-Åsberg Depression Rating Scale (MADRS) and/or Hamilton Anxiety Rating Scale (HAM-A) total score from baseline; remission defined as MADRS and/or HAM-A total s

SUBMITTER: Christensen MC 

PROVIDER: S-EPMC9112621 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature